Combining Ambrisentan and Tadalafil provides improved treatment outcome in PAH

Combination of Ambrisentan and Tadalafil

Pharmacological agents with different mechanisms of action are often used in combination for the treatment of many health conditions. There is the proposition in medicine that combining pharmacological agents with different mechanisms generally provides superior results than increasing the dosage of a single agent. When we increase the dosage of a medication, every increment of efficacy is coupled with an increase in the risk for adverse effects. Combining agents with different mechanisms of actions can often produce the same desired therapeutic effect at lower doses of each agent. In the treatment of pulmonary hypertension, the combination associated with the best efficacy that we know today, is the combination of tadalafil and ambrisentan for patients with WHO functional class II or III pulmonary arterial hypertension (PAH). Continue reading

Ambrisentan for the treatment of pulmonary hypertension (PAH)

What is Ambrisentan?

Ambrisentan (brand named Letairis in the U.S., Volibris in the European Union and Canada) is an FDA-approved oral medication for the treatment of pulmonary hypertension. It is recommended by the FDA for patients with WHO class II and class III symptoms of pulmonary arterial hypertension (PAH) to improve exercise tolerance and slow down disease progression. The price for ambrisentan is over $10,000 per month in many countries, you can buy ambrisentan from our online pharmacy at an affordable price.

Ambrisentan is an endothelin receptor antagonist (ETA). It selectively inhibits the endothelin type-A (ETA) receptor. Endothelin-1 (ET-1) is a protein molecule our body makes for the purpose of cell to cell signaling. and ETA and ETB are receptors for ET-1 found on the smooth muscle cells of our blood vessels to mediate the effect of ET-1. When ET-1 binds with ETA  receptors, the blood vessels constrict, and blood pressure rises. When ET-1 binds with ETB receptors, the blood vessels dilate, and blood pressure drops. Continue reading

FG-3019 (Pamrevlumab) to show reversal of pulmonary fibrosis in Phase-II study

An investigational drug code named FG-3019 developed by FibroGen Inc. caught headlines recently after FibroGen published results of its recently concluded preliminary Phase-II study. The study was published in the European Respiratory Journal, in an article titled “FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in IPF.” Continue reading

Study shows statins can improve IPF patient outcomes

The study “Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis,” was recently published in the journal Thorax. The researchers in this study compiled patient outcome data from all of the previous 3 major clinical trials on pirfenidone, the two CAPACITY trials and the ASCEND trial.

The combined patient data was analyzed based on those patients who were taking statin drugs during the clinical trials and patients who were not taking statin drugs. Among all the patients, 276 (44%) patients were statin users and 348 (56%) did not use statins. Both groups had similar characteristics at baseline, but the statin users were on average older and had higher prevalence of cardiovascular disease. Continue reading